TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects

Cancer Research

Volumn 71, Issue 20, 2011, Pages 6382-6390

  Sommariva, Michele ^a   De Cecco, Loris ^b   De Cesare, Michelandrea ^b   Sfondrini, Lucia ^a   Meńard, Sylvie ^b   Melani, Cecilia ^b   Delia, Domenico ^b   Zaffaroni, Nadia ^b   Pratesi, Graziella ^b   Uva, Valentina ^a   Tagliabue, Elda ^b   Balsari, Andrea ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; DNA REPAIR PROTEIN; ESTROGEN RECEPTOR; GENE PRODUCT; IMIQUIMOD; RAD23B PROTEIN; RAD51C PROTEIN; RAD54B PROTEIN; SIRTUIN 1; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES FLUID; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RELAPSE; CANCER SURVIVAL; COLON CARCINOMA; COMPUTER MODEL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA MICROARRAY; DNA REPAIR; DNA REPAIR GENE; DOWN REGULATION; DRUG SENSITIVITY; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RAD23B GENE; RAD51C GENE; RAD54B GENE; RELAPSE FREE SURVIVAL; SIRT1 GENE; SPLEEN CELL; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CELL LINE, TUMOR; CISPLATIN; COLONIC NEOPLASMS; DNA REPAIR; DOWN-REGULATION; FEMALE; HUMANS; MICE; OLIGODEOXYRIBONUCLEOTIDES; OVARIAN NEOPLASMS; SPLEEN; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME; UP-REGULATION;

EID: 80054048790     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1285     Document Type: Article

References (48)

1. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511. (Pubitemid 38931765)
2. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95. (Pubitemid 41057715)
3. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007;4:289-94. (Pubitemid 47036451)
4. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004;6:88-95. (Pubitemid 38898835)
5. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184-94. (Pubitemid 46718403)
6. Pratesi G, Petrangolini G, Tortoreto M, Addis A, Belluco S, Rossini A, et al. Therapeutic synergism of gencitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 2005;65:6388-93. (Pubitemid 40994426)
7. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999;59:5429-32. (Pubitemid 29526450)
8. De Cesare M, Calcaterra C, Pratesi G, Gatti L, Zunino F, Ménard S, et al. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin Cancer Res 2008;14:5512-8.
9. Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, Shannon M, et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 2006;29:558-68. (Pubitemid 44395280)
10. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008;27:161-7.
11. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008;31:520-7.
12. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, et al. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007;13:6168-74. (Pubitemid 350075077)
13. Weiner GJ. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies. Adv Drug Deliv Rev 2009;61:263-7.
14. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotideTLR9 agonists.AdvDrug Deliv Rev 2009;61:195-204.
15. Jahrsdorfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008;3:27-32. (Pubitemid 351410539)
16. Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 2009;58:615-28.
17. Petrangolini G, Tortoreto M, Perego P, Carenini N, De Cesare M, Balsari A, et al. Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer Biol Ther 2008;7:596-601. (Pubitemid 351847037)
18. Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R, et al. Combination of CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 2004;40:1275-81. (Pubitemid 38526349)
19. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003;9:3105-14. (Pubitemid 36993273)
20. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005;11:361-9. (Pubitemid 40075816)
21. Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 2004;64:5074-7. (Pubitemid 39006521)
22. Mason KA, Neal R, Hunter N, Ariga H, Ang K, Milas L. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiother Oncol 2006;80:192-8. (Pubitemid 44314019)
23. Zheng L, Asprodites N, Keene AH, Rodriguez P, Brown KD, Davila E. TLR9 engagement on CD4 T lymphocytes represses gamma-radiation-induced apoptosis through activation of checkpoint kinase response elements. Blood 2008;111:2704-13.
24. De Cesare M, Sfondrini L, Campiglio M, Sommariva M, Bianchi F, Perego P, et al. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. J Immunother 2010;33:8-15.
25. Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985;45:4970-9. (Pubitemid 16236181)
26. Klaschik S, Tross D, Klinman DM. Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo. J Leukoc Biol 2009;85:788-95.
27. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996;93:2879-83. (Pubitemid 26116242)
28. Takeshita S, Takeshita F, Haddad DE, Ishii KJ, Klinman DM. CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression. Cell Immunol 2000;206:101-6. (Pubitemid 32121622)
29. Ishii KJ, Takeshita F, Gursel I, Gursel M, Conover J, Nussenzweig A, et al. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J Exp Med 2002;196:269-74. (Pubitemid 34787517)
30. Zelenay S, Elias F, Flo J. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides. Eur J Immunol 2003;33:1382-92. (Pubitemid 36609157)
31. Datta N, Mukherjee S, Das L, Das PK. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation. Eur J Immunol 2003;33:1508-18. (Pubitemid 36790411)
32. Ito S, Ishii KJ, Gursel M, Shirotra H, Ihata A, Klinman DM. CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol 2005;174:777-82. (Pubitemid 40094272)
33. Pesce I, Monaci E, Muzzi A, Tritto E, Tavarini S, Nuti S, et al. Intranasal administration of CpG induces a rapid and transient cytokine response followed by dendritic and natural killer cell activation and recruitment in the mouse lung. J Innate Immun 2010;2:144-59.
34. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008;105:10501-6.
35. Westwood JA, Haynes NM, Sharkey J, McLaughlin N, Pegram HJ, Schwendener RA, et al. Toll-like receptor triggering and T-cell costimulation induce potent antitumor immunity in mice. Clin Cancer Res 2009;15:7624-33.
36. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7. (Pubitemid 43128862)
37. Van de Vijver MJ, He YD, Van'T Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
38. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 2009;112:275-81.
39. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-62. (Pubitemid 26043653)
40. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000;164:944-53.
41. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000;164:1617-24. (Pubitemid 30067282)
42. Agrawal S, Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 2007;35:1461-7.
43. Lu H, Wagner WM, Gad E, Yang Y, Duan H, Amon LM, et al. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 2010;184:5360-7.
44. Schild D, Wiese C. Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. Nucleic Acids Res 2010;38:1061-70.
45. Uhl M, Csernok A, Aydin S, Kreienberg R, Wiesmuller L, Gatz SA. Role of SIRT1 in homologous recombination. DNA Repair (Amst) 2010;9:383-93.
46. Murad YM, Clay TM, Lyerly HK, Morse MA. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther 2007:1257-66. (Pubitemid 47305250)
47. Torri A, Beretta O, Ranghetti A, Granucci F, Ricciardi-Castagnoli P, Foti M. Gene expression profiles identify inflammatory signatures in dendritic cells. PLoS One 2010;5:e9404.
48. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005;5:446-58. (Pubitemid 40835033)